Merck & Co Inc


  • Merck, Iowa firm sign Ebola vaccine licensing deal Monday, 24 Nov 2014 | 1:28 PM ET

    TRENTON, N.J.— Merck& Co., a top creator and seller of vaccines, has joined the fight against Ebola, the often-fatal hemorrhagic virus that's been ravaging parts of West Africa for months. The exclusive deal involves rVSV-EBOV, a vaccine candidate under early development by BioProtection Systems, the vaccine-development subsidiary of NewLink Genetics Corp. of...

  • Nov 24- Merck& Co Inc on Monday said it would buy worldwide commercial rights to NewLink Genetics Corp's experimental vaccine meant to prevent infection with the Ebola virus. Guinea, Sierra Leone and Liberia account for all but 15 of the deaths. The Walter Reed Army Institute of Research and the U.S. National Institute of Allergy and Infectious Diseases, part of...

  • Nov 24- Merck& Co Inc will buy worldwide commercial rights to NewLink Genetics Corp's experimental Ebola vaccine. The Public Health Agency of Canada, which originally developed the vaccine, will retain non-commercial rights to the drug. The U.S. National Institutes of Health has announced plans to start a large late-stage study of the vaccine in early 2015..

  • Health care M&A leads global deal surge Sunday, 23 Nov 2014 | 9:01 AM ET

    "Health care has been a sleepy niche of M&A until recently, but the giant has been awakened," says Ken Menges, a senior partner handling M&A at law firm Akin Gump in New York. To a large extent, the deals are being driven by "cost pressure on the entire health care system," as insurers and government health plans increasingly hold down or even reduce reimbursements to drug,...

  • Losing Allergan deals blow to Valeant reputation Monday, 17 Nov 2014 | 1:25 PM ET

    WINNIPEG/ NEW YORK Nov 17- The failure of Valeant Pharmaceuticals International Inc to buy Allergan Inc leaves it with nothing to show for a seven-month, bruising pursuit. Losing Allergan to Actavis PLC also hurts Valeant's deal-making reputation, said a source close to the company not authorized to speak publicly. Allergan's rebuff will embolden future...

  • CHICAGO, Nov 17- After years of uncertainty, a nearly decade-long study showed that Merck& Co's cholesterol drug Zetia lowered the risk of heart attacks and strokes in high-risk heart patients when used with an effective statin. Christopher Cannon, lead investigator of the 18,144- patient Improve-It study presented at the American Heart Association...

  • CHICAGO, Nov 17- Regeneron Corp's experimental drug alirocumab helped 10 times as many high-risk patients unable to tolerate widely-used statins get their "bad" LDL cholesterol down to target levels than Merck& Co's Zetia, according to data from a clinical trial presented on Monday. Alirocumab, developed along with French drugmaker Sanofi, belongs to a new...

  • European shares close higher after Draghi speaks Monday, 17 Nov 2014 | 11:44 AM ET

    European shares closed higher after ECB President Mario Draghi reiterated that he was willing to do more to stimulate the euro zone economy.

  • Actavis to spend $66 billion on Allergan Monday, 17 Nov 2014 | 9:32 AM ET

    Actavis, which is buying Botox-maker Allergan for $66 billion in one of the biggest acquisitions announced so far this year, plans to stay committed to developing new products. Actavis and the company it outbid for Allergan, Valeant Pharmaceuticals, both have grown rapidly in recent years through multibillion dollar acquisitions of other drugmakers.

  • Stock futures decline as Japan slides into recession Monday, 17 Nov 2014 | 9:17 AM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks looked set to decline at the open on Monday, with global shares hit by the news that Japan had unexpectedly slipped into recession.

  • Study lifts cloud over heart drugs Zetia, Vytorin Monday, 17 Nov 2014 | 8:53 AM ET

    CHICAGO— A major study lifts a cloud around Zetia and Vytorin, blockbuster drugs for lowering cholesterol. Merck& Co.' s ezetimibe, which went on sale in 2002, lowers cholesterol in a different way. The drug won Food and Drug Administration approval for lowering LDL, but some studies suggested that might not translate to fewer heart attacks and strokes.

  • US stocks seen lower after Japan enters recession Monday, 17 Nov 2014 | 6:03 AM ET
    Traders on the floor of the New York Stock Exchange.

    U.S. stocks looked set to decline at the open on Monday, with global shares hit by the news that Japan had unexpectedly slipped into recession.

  • German Merck, Pfizer in immunotherapy deal Monday, 17 Nov 2014 | 5:47 AM ET

    Germany's Merck KGaA said Monday it struck an alliance over cancer immunotherapy drugs with Pfizer, triggering an upfront payment of $850 million by the U.S. drugmaker.

  • Nov 16- Chemotherapy as a treatment for advanced melanoma could soon become obsolete, researchers said on Sunday, after patients taking an experimental immuno-oncology drug from Bristol-Myers Squibb Co had a much higher survival rate and had other favorable results. Georgina Long, an associate professor at the Melanoma Institute Australia who helped lead...

  • Stocks little moved, with S&P 500 and Dow at records Tuesday, 11 Nov 2014 | 4:16 PM ET
    Trader on the floor of the New York Stock Exchange.

    U.S. stocks ended near highs on Tuesday, with the Dow and S&P each edging up to a record close.

  • Nov 11- AbbVie Inc said its experimental drug that treats genotype 4 hepatitis C showed high response rates in a mid-stage study in patients who have been considered difficult to treat. AbbVie said on Tuesday 100 percent of the patients who were given the drug and had failed previous treatment showed high response rates at 12 weeks after the treatment.

  • Lighting Round: This one is a strong buy Monday, 10 Nov 2014 | 7:09 PM ET

    Are you ready skeedaddy???!!! It's time for the Lightning Round. Cramer makes the call on viewer favorites.

  • Arrowhead CEO: We feel 'great' about the drug Monday, 10 Nov 2014 | 6:55 PM ET

    Arrowhead Research Chief Executive Chris Anzalone contends the company's hepatitis B therapy, ARC-520, has potential.

  • Merck: 4-week hepatitis C treatment too short Monday, 10 Nov 2014 | 6:52 PM ET
    Employees walk past a Merck sign in front of the company's building in Summit, New Jersey.

    Merck hoped to trump Gilead's hepatitis C treatment with its own shorter therapy, but early results show the four-week regimen may not be successful.

  • Cramer's military salute: Long-term investing keys Monday, 10 Nov 2014 | 6:10 PM ET

    Jim Cramer focuses on three long-term investment themes specialized for veterans and active-duty soldiers.